Highbridge Capital Management and Gamida Cell secure court-approved creditors’ arrangement plan
This plan will allow Gamida Cell to continue its operations as an Israeli private company, wholly owned by Highbridge.
NY-headquartered Highbridge Capital Management, LLC is a multi-strategy alternative investment management firm, while Israel’s Gamida Cell is a biopharmaceutical company specializing in the development of advanced cell therapies to treat blood cancers and serious blood disorders.
Herzog acted as Israeli counsel to Highbridge in this significant transaction, with its team led by Ron Ben-Menachem (Capital Markets), Yaniv Dinovitch (Litigation), Nir Dash (Co-head of Capital Markets), Gilad Wekselman (Co-head of Litigation), Neri Lavie (Litigation), Mohammad Mawasi (Capital Markets), Dr. Ehab Farah (Tax), Ofer Granot(Innovation Authority), and Maayan Hammer-Tzeelon (Employment).
Meitar advised Gamida Cell, with the team including Pinni Yaniv, Haim Gueta, Merav Ben Artzi, and Daniel Colthof.
